Abstract：Ovarian cancer is a common gynecology oncologic tumor. Its clinical presentations are untypical, mainly including abdominal distension and pelvic mass, et al. The pathologic types of ovarian cancer are varied, so its heterogenicity is obvious. Tumor cell line modals and transgenic animal modals are commonly used ovarian cancer models, and they gain great progress in ovarian cancer researches. But their defects are also inevitable. Ovarian cancer patient derived tumer xenograft (PDX) model is a brand new cancer research model, we summarize the application base and prospect of it PDX model ovarian cancer researches.
李巍 杨淑丽 田明 苗劲蔚▲. PDX模型在卵巢癌研究中的应用展望[J]. 中国医药导报, 2019, 16(18): 45-48.
LI Wei YANG Shuli TIAN Ming MIAO Jinwei▲. Application and prospect of PDX model in ovarian cancer researches. 中国医药导报, 2019, 16(18): 45-48.
[1] Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer [J]. Surg Oncol Clin N Am，2012，21（4）：645-663.
[2] Narasimhulu DM，Khoury-Collado F，Chi DS. Radical surgery in ovarian cancer [J]. Curr Oncol Rep，2015，17（4）：439.
[3] Dulbecco R. Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus [J]. Proc Natl Acad Sci U S A，1952，38（8）：747-752.
[4] Sawyers C. Targeted cancer therapy [J]. Nature，2004，4329（7015）：294-297.
[5] Roschke AV，Tonon G，Gehlhaus KS，et al. Karyotypic complexity of the NCI-60 drug-screening panel [J]. Cancer Res，2003，63（24）：8634-8647.
[6] Stephens PJ，Tarpey PS，Davies H，et al. The landscape of cancer genes and mutational processes in breast cancer [J]. Nature，2012，486（7043）：400-404.
[7] Bobbs AS，Cole JM，Cowden Dahl KD. Emerging and Evolving Ovarian Cancer Animal Models [J]. Cancer Growth Metastasis，2015，8（Suppl 1）：29-36.
[8] Hiroshima Y，Zhang Y，Zhang N，et al. Establishment of a Patient-Derived Orthotopic Xenograft （PDOX） Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic Pattern [J]. PLoS One，2015，10（2）：e0117417.
[9] Kawaguchi T，Foster BA，Young J，et al. Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research [J]. J Mammary Gland Biol Neoplasia，2017，22（2）：131-139.
[10] Wu J，Liu X，Nayak SG，et al. Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele [J]. PLoS One，2017，12（9）：e0184984.
[11] Lai Y，Wei X，Lin S，et al. Current status and perspectives of patient-derived xenograft models in cancer research [J]. J Hematol Oncol，2017，10（1）：106.
[12] Chijiwa T，Kavai K，Noguchi A，et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice [J]. Int J Oncol，2015，47（1）：61-70.
[13] Jung J，Seol HS，Chang S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research [J]. Cancer Res Treat，2018，50（1）：1-10.
[14] Colombo PE，du Manoir S，Orsett B，et al. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.Pierre-Emmanuel Colombo [J]. Oncotarget，2015，6（29）：28 327-28 340.
[15] Lee WS，Kim HY，Seok JY，et al. Genomic profiling of patient-derived colon cancer xenograft models [J]. Medicine （Baltimore），2014，93（28）：e298.
[16] Wang X，Fu X，Hoffman RM. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice [J]. Int J Cancer，1992，51（6）：992-995.
[17] Cassoux N，Thuleau A，Assayag F，et al. Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical Testing [J]. Ocul Oncol Pathol，2015，1（3）：200-206.
[18] Erriquez J，Olivero M，Mittica G，et al. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer [J]. Oncotarget，2016，24（3）：26 181-26 191.
[19] George E，Kim H，Krepler C，et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers [J]. JCI Insight，2017，2（1）：e89760.
[20] Ricci F，Bizzaro F，Cesca M，et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations [J]. Cancer Res，2014，74（23）：6980-6990.
[21] Topp MD，Hartley L，Cook M，et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts [J]. Mol Oncol，2014， 8（3）：656-668.
[22] Ricci F，Fratelli M，Guffanti F，et al. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge：a new experimental setting to study response to therapy [J]. Oncotarget，2017，8（5）：7441-7451.
[23] Ricci F，Guffanti F，Damia G，et al. Combination of paclitaxel，bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts [J]. Mol Cancer，2017，16：97.
[24] Guffanti F，Fratelli M，Ganzinelli M，et al. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts [J]. Oncotarget，2018，9（37）：24 707-24 717.
[25] Eirew P，Steif A，Khattra J，et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution [J]. Nature，2015，518：422-426.
[26] Morton JJ，Bird G，Keysar SB，et al. XactMice：humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer [J]. Oncoqene， 2016，35（3）：290-300.
[27] Wetterauer C，Vlajnic T，Schüler J，et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocopromised mice [J]. Prostate，2015，75（60）：585-592.
[28] Zhang L，Liu Y，Wang X，et al. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice [J]. Sci Rep，2015，30（5）：9447.
[29] Ben-David U，Ha G，Tseng YY，et al. Patient-derived xenografts undergo mouse-specific tumor evolution [J]. Nat Genet，2017，49（11）：1567-1575.
2019, Vol. 16 
京公网安备 11010502046598号